GILD catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedNo phase registeredNCT00825929Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.Radboud University Medical Center · HIV Infections
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT03964727Study of Sacituzumab Govitecan in Participants With Metastatic Solid TumorsGilead Sciences · Metastatic Solid TumorActive, not recruitingGILDLead
- Enrollment
- Locked
- Primary completion
- Jan 15, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT04617522Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentGilead Sciences · Advanced or Metastatic Solid TumorRecruitingGILDLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04639986Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Gilead Sciences · Metastatic Breast CancerActive, not recruitingGILDLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT05143229Alpelisib And Sacituzumab Govitecan For Treatment Of Breast CancerUniversity of Kansas Medical Center · Breast CancerActive, not recruitingGILDCollaboratorNVSCollaborator
- Enrollment
- Locked
- Primary completion
- Jan 28, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05396885Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Kite, A Gilead Company · Multiple MyelomaActive, not recruitingGILDLeadACLXCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05866523Teamwork Makes the Dream WorkLoma Linda University · HIV InfectionsRecruitingGILDCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT06082960Study of GS-9911 With or Without Antibody Treatment for Adults With Solid TumorsGilead Sciences · Solid TumorsActive, not recruitingGILDLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06104592Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCLH. Lee Moffitt Cancer Center and Research Institute · Large B-cell LymphomaRecruitingGILDCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07163481A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic...Hunan Cancer Hospital · Stage IV (Metastatic) Breast CancerNot yet recruitingGILDCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06682728Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk RecurrenceUniversity of California, Irvine · Urothelial CarcinomaRecruitingGILDCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06539052MIGrant Reflex Test HDV (MIGRED) ProjectUniversity of Campania Luigi Vanvitelli · Hepatitis D Virus InfectionNot yet recruitingGILDCollaborator
- Enrollment
- Locked
- Primary completion
- Jun 20, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05675579A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage...M.D. Anderson Cancer Center · Breast CancerActive, not recruitingGILDCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06830668Same-Day Restart of B/F/TAF in HIV Patients After NNRTI DiscontinuationNational Center for AIDS/STD Control and Prevention, China CDC · HIV InfectionNot yet recruitingGILDCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05089734Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Gilead Sciences · Non-Small Cell Lung CancerActive, not recruitingGILDLead
- Enrollment
- Locked
- Primary completion
- Nov 29, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05327530A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma...EMD Serono Research & Development Institute, Inc. · Locally Advanced or Metastatic Urothelial CarcinomaActive, not recruitingGILDCollaboratorNKTRCollaborator
- Enrollment
- Locked
- Primary completion
- Jun 20, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03971409Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple...Laura Huppert, MD, BA · Stage III Breast CancerActive, not recruitingPFECollaboratorGILDCollaborator
- Enrollment
- Locked
- Primary completion
- Jan 31, 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 17 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.